Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Allspring Global Investments Holdings LLC Cuts Stake in Charles River ...

AI-generated analysis

📉 Allspring Global Investments Holdings LLC lowered its CRL stake by 0.1% in Q1, selling 2,280 shares while retaining 1,993,316 shares worth $348.6 million.

🏦 Institutional ownership remains high at 98.91%, with new stakes added by Tema Etfs LLC, Los Angeles Capital Management LLC, Sfam LLC, and Elyxium Wealth LLC in Q4.

📈 Activest Wealth Management significantly increased its position by 10,900.0% to own 220 shares valued at $44,000 after purchasing an additional 218 shares.

💰 Director James C. Foster sold 75,000 shares for $16.875 million under a pre-arranged Rule 10b5-1 trading plan on June 29th.

📊 The stock trades at a market cap of $11.03 billion with a P/E ratio of -60.93 and a beta of 1.40.

🎯 Analyst consensus target price is $220.75 with an average rating of 'Moderate Buy' based on twelve buy, three hold, and one sell ratings.

📈 Barclays raised its price target to $220 with an 'overweight' rating, while Citigroup reiterated a 'buy' rating in recent reports.

📉 JPMorgan Chase lowered its price objective to $160 and assigned a 'neutral' rating in a research note from April 13th.

🎯 BNP Paribas Exane set a $250 price objective for the stock in a report dated July 1st.

📉 Mizuho raised its target price to $230 and maintained a 'neutral' rating following an update on Monday.

🏢 Charles River Laboratories International provides discovery, safety assessment, toxicology, and pathology services for the pharma industry.

🧬 The company supplies laboratory animals and related diagnostics to support drug development from early discovery through regulatory submission.

Bullish Signals
  • Analyst consensus target price of $220.75 suggests potential upside if the stock trades below this level, with Citigroup maintaining a 'buy' rating.
  • Barclays upgraded its stance to 'overweight' and raised the price target to $220, indicating confidence in the company's growth prospects.
  • Mizuho increased its price objective to $230, reflecting positive sentiment regarding the company's strategic position.
  • BNP Paribas Exane set a high price objective of $250, signaling strong long-term potential for the stock.
  • Activest Wealth Management significantly expanded its holdings by 10,900.0%, demonstrating strong institutional interest despite the small absolute share count.
Risk Factors
  • JPMorgan Chase lowered its price objective to $160 and assigned a 'neutral' rating, indicating caution or lack of immediate upside.
  • The stock has a negative P/E ratio of -60.93, suggesting the company is currently unprofitable on a trailing basis.
  • Director James C. Foster sold 75,000 shares representing over 70% of his holdings, which could be interpreted as a lack of confidence in near-term performance.
Full Analysis
Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (CRL) by 0.1% during the first quarter, selling 2,280 shares to hold a remaining position of 1,993,316 shares valued at approximately $348.6 million. This holding represents about 0.6% of Allspring's total portfolio and ranks as its 25th largest position. The filing indicates that institutional investors collectively own 98.91% of the company's outstanding stock. Other institutional activity includes new positions from Tema Etfs LLC, Los Angeles Capital Management LLC, Sfam LLC, Elyxium Wealth LLC, and a significant increase in Activest Wealth Management's holdings, which grew by 10,900.0% to own 220 shares valued at $44,000. Meanwhile, Director James C. Foster executed a pre-arranged Rule 10b5-1 plan sale on June 29th, offloading 75,000 shares for $16.875 million, reducing his personal ownership by over 70% to 31,596 shares. Analyst sentiment remains mixed with a consensus target price of $220.75 and an average rating of 'Moderate Buy.' Recent reports include Barclays raising its target to $220 with an 'overweight' rating, Citigroup maintaining a 'buy' rating, and Mizuho increasing its target to $230. Conversely, JPMorgan Chase lowered its price objective to $160 with a 'neutral' rating, while BNP Paribas Exane set a $250 price objective. The stock currently trades near its 52-week high of $237.86. Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers core offerings including discovery, safety assessment, toxicology, and pathology services, alongside the supply of laboratory animals and diagnostics to help clients accelerate drug development from early discovery through regulatory submission.